Skip to content

Prospective Study for Symptomatic Relief of ET With Cala Therapy

Prospective Study for Symptomatic Relief of Essential Tremor With Cala Therapy

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03597100
Acronym
PROSPECT
Enrollment
263
Registered
2018-07-24
Start date
2018-12-14
Completion date
2019-05-29
Last updated
2023-10-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Essential Tremor

Brief summary

Prospective, multi-center, single-arm, non-significant risk study designed to evaluate the Cala TWO device. Subjects will be screened for eligibility and fitted with a Cala TWO device. Subjects will wear the device at home for a period of 3 months, during which they will be asked to stimulate their dominant hand twice a day. The stimulation amplitude will be based on each subject's stimulation threshold. Subjects will have in clinic assessments at enrollment, month 1 and 3.

Interventions

DEVICECala TWO

Wrist-worn stimulator which applies a tremor-customized stimulation pattern to an individual's nerves

Sponsors

Cala Health, Inc.
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
22 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Must be ≥22 years of age * Competent and willing to provide written, informed consent to participate in the study * A diagnosis of essential tremor as confirmed from clinical history and examination by a movement disorder neurologist * A tremor severity score of 2 or above in the dominant hand/arm as measured by any one of the TETRAS upper limb items and a minimum subset score of 6 across all upper limb items * Significant disability due to essential tremor (Bain & Findley score of 3 or above in any one of the upper limb items and a minimum subset score of 8 across all upper limb items) * Stable dose of tremor medications, if applicable, for 30 days prior to study entry * Stable dose of antidepressant medications, if applicable, for 90 days prior to study entry * Willing to comply with study protocol requirements including: * remaining on a stable dosage of tremor and antidepressant medications, if applicable, during the duration of the study * no significant alcohol or caffeine consumption within 8 hours prior to study visits * no usage of the Cala TWO device within 8 hours prior to study visits

Exclusion criteria

* Moderate to severe ethanol dependence as defined by the criteria outlined in the DSM-5 (score of 4 or higher) * Implanted electrical medical device, such as a pacemaker, defibrillator, or deep brain stimulator, or implanted metal in the wrist to be stimulated * Previous thalamotomy procedure, including stereotactic thalamotomy, gamma knife radiosurgical thalamotomy, and focused ultrasound for the treatment of tremor * Suspected or diagnosed epilepsy or other seizure disorder * Swollen, infected, inflamed areas, or skin eruptions, open wounds, or cancerous lesions of skin at stimulation site * Peripheral neuropathy affecting the tested upper extremity * Presence of any other neurodegenerative disease like Parkinson-plus syndromes suspected on neurological examination. These include: multisystem atrophy, progressive supranuclear palsy, dementia with Lewy bodies, and Alzheimer's disease. * Anyone suspected to have the diagnosis of idiopathic Parkinson's disease (PD). This includes excluding anyone with the presence of parkinsonian features including bradykinesia rigidity, or postural instability. Subjects who exhibit only mild resting tremor but no other symptoms or signs of PD may be included. * Botulinum toxin injection for hand tremor within 6 months prior to study enrollment * Are participating or have participated in another interventional clinical trial in the last 30 days which may confound the results of this study, unless approved by the Sponsor * Significant alcohol or caffeine consumption within 8 hours prior to study enrollment, which may confound the results of the study, where significant caffeine is considered more than 95 mg (equivalent to a cup of coffee), and significant alcohol is considered more than 14 g (equivalent to 5 oz of wine, 12 oz of beer, or 1.5 oz of distilled spirits). * Subjects unable to communicate with the investigator and staff * Any health condition that in the investigator's opinion should preclude participation in this study * Pregnancy or anticipated pregnancy during the course of the study

Design outcomes

Primary

MeasureTime frameDescription
TRG (Tremor Research Group) Essential Tremor Rating Assessment Scale (TETRAS) Subset ScoreBaseline to 3-monthsTremor Research Group (TRG) Essential Tremor Rating Assessment Scale (TETRAS) subset score: TETRAS subset score relevant to the stimulated upper limb. The subset score is the sum of 6 rated tasks. Each task is rated 0 to 4, where a higher score indicates more severe tremor. Minimum subset score = 0; Maximum subset score = 24.
Bain & Findley Activities of Daily Living (ADL) Scale Subset ScoreBaseline to 3-monthsBain & Findley ADL subset score relevant to the stimulated upper limb. The subset score is the sum of 8 rated tasks. Each task is rated 1 to 4, where a higher score indicates more severe tremor. Minimum subset score = 8; Maximum subset score = 32.

Secondary

MeasureTime frameDescription
Kinematic Measurements, as Collected With the Device During Postural Holds, Change From Pre-stimulation to Post-stimulation Across SessionsAverage change in tremor power over 3-month study periodSubjects will be prompted to perform a postural hold task before and after each stimulation session. During this task, the device will record kinematic data using on-board motion sensors to objectively assess if there are any changes in tremor level. The change in each patient's pre- and post-stimulation tremor power was defined as the median change over all valid stimulation sessions. Sample mean and standard deviations were computed using the median change value from all patients.

Countries

United States

Participant flow

Participants by arm

ArmCount
Cala TWO
Two 40-minute stimulation sessions daily, separated by at least two hours Cala TWO: Wrist-worn stimulator which applies a tremor-customized stimulation pattern to an individual's nerves
263
Total263

Baseline characteristics

CharacteristicCala TWO
Age, Continuous69.6 years
STANDARD_DEVIATION 10.1
Ethnicity (NIH/OMB)
Hispanic or Latino
7 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
253 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
3 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
Race (NIH/OMB)
Asian
11 Participants
Race (NIH/OMB)
Black or African American
7 Participants
Race (NIH/OMB)
More than one race
3 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
Race (NIH/OMB)
Unknown or Not Reported
5 Participants
Race (NIH/OMB)
White
237 Participants
Region of Enrollment
United States
263 participants
Sex: Female, Male
Female
137 Participants
Sex: Female, Male
Male
126 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
1 / 263
other
Total, other adverse events
47 / 263
serious
Total, serious adverse events
5 / 263

Outcome results

Primary

Bain & Findley Activities of Daily Living (ADL) Scale Subset Score

Bain & Findley ADL subset score relevant to the stimulated upper limb. The subset score is the sum of 8 rated tasks. Each task is rated 1 to 4, where a higher score indicates more severe tremor. Minimum subset score = 8; Maximum subset score = 32.

Time frame: Baseline to 3-months

ArmMeasureGroupValue (MEAN)Dispersion
Cala TWOBain & Findley Activities of Daily Living (ADL) Scale Subset ScoreBaseline18.4 score on a scaleStandard Deviation 3.8
Cala TWOBain & Findley Activities of Daily Living (ADL) Scale Subset ScoreFinal Visit13.4 score on a scaleStandard Deviation 4.4
Cala TWOBain & Findley Activities of Daily Living (ADL) Scale Subset ScoreChange-4.98 score on a scaleStandard Deviation 4.3
Primary

TRG (Tremor Research Group) Essential Tremor Rating Assessment Scale (TETRAS) Subset Score

Tremor Research Group (TRG) Essential Tremor Rating Assessment Scale (TETRAS) subset score: TETRAS subset score relevant to the stimulated upper limb. The subset score is the sum of 6 rated tasks. Each task is rated 0 to 4, where a higher score indicates more severe tremor. Minimum subset score = 0; Maximum subset score = 24.

Time frame: Baseline to 3-months

ArmMeasureGroupValue (MEAN)Dispersion
Cala TWOTRG (Tremor Research Group) Essential Tremor Rating Assessment Scale (TETRAS) Subset ScoreBaseline12.6 score on a scaleStandard Deviation 2.7
Cala TWOTRG (Tremor Research Group) Essential Tremor Rating Assessment Scale (TETRAS) Subset ScoreFinal Visit9.8 score on a scaleStandard Deviation 3.5
Cala TWOTRG (Tremor Research Group) Essential Tremor Rating Assessment Scale (TETRAS) Subset ScoreChange-2.8 score on a scaleStandard Deviation 2.8
Secondary

Kinematic Measurements, as Collected With the Device During Postural Holds, Change From Pre-stimulation to Post-stimulation Across Sessions

Subjects will be prompted to perform a postural hold task before and after each stimulation session. During this task, the device will record kinematic data using on-board motion sensors to objectively assess if there are any changes in tremor level. The change in each patient's pre- and post-stimulation tremor power was defined as the median change over all valid stimulation sessions. Sample mean and standard deviations were computed using the median change value from all patients.

Time frame: Average change in tremor power over 3-month study period

ArmMeasureValue (MEAN)Dispersion
Cala TWOKinematic Measurements, as Collected With the Device During Postural Holds, Change From Pre-stimulation to Post-stimulation Across Sessions-0.8 (m/s^2)^2Standard Deviation 3.7

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026